News MediWound Ltd.

Equities

MDWD

IL0011316309

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
17.59 ^USD	+7.19%		+0.86%	+72.96%

Mar. 21	MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	CI
Mar. 21	Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	Mar. 21	CI
Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M	Mar. 21	MT
MediWound: Q4 Earnings Snapshot	Mar. 21	AQ
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	Mar. 21	GL
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	Mar. 14	GL
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	Mar. 14	AQ
Sector Update: Health Care Stocks Mixed Late Afternoon	Feb. 12	MT
MediWound Shares Rise After Positive Results From EscharEx Comparison Study	Feb. 12	MT
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study	Feb. 12	GL
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study	Feb. 12	CI
MediWound to Participate in Two Upcoming Investor Conferences	Feb. 05	GL
MediWound to Participate in Two Upcoming Investor Conferences	Feb. 05	AQ
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA	Jan. 09	MT
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	Jan. 09	GL
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	Jan. 09	AQ
Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns	Jan. 09	CI
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army	Dec. 29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News MediWound Ltd.

Equities

MDWD

IL0011316309

Summary

Filters